Request Trial
lava-flow
1 April 2013AsiaRahul Vartak

Slow but positive change? The evolution of section 3d

The Indian pharmaceutical scene has been plagued by Section 3d of the Indian Patents Act for almost a decade. Section 3d has been wielded skilfully by various companies for challenging pharmaceutical patents. Various tactics have been used by innovators for overcoming the challenges posed by Section 3d, including a challenge to TRIPS compliance and constitutional validity. However, Section 3d has been able to withstand all challenges.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Asia
Takeda’s China IP head: What pharma is still getting wrong
27 May 2026   China’s IP system is undergoing real change. Takeda’s IP head for the region explains what that looks like on the ground and why the old playbook no longer cuts it.
Asia
Healthcare leads sweeping AI partnership in Singapore
20 May 2026   Backed by the country’s wider AI ambitions, Google has signed a deal to roll out healthcare, scientific research, and safety initiatives.
Asia
IndiaMart v CDSCO: A test of intermediary liability
31 March 2026   The clash between one of India’s largest B2B marketplaces and the country’s drugs regulator challenges the “passive” position of such platforms with regards to allegedly unlawful pharmaceutical listings, says Aarti Aggarwal of Remfry & Sagar.


Editor's picks

Takeda to appeal $885m jury verdict over ‘pay-for-delay’ scheme
Americas
Takeda to appeal $885m jury verdict over ‘pay-for-delay’ scheme
19 May 2026

Editor's picks

Americas
Takeda to appeal $885m jury verdict over ‘pay-for-delay’ scheme
19 May 2026
Americas
From the courtroom: Hikma v Amarin SCOTUS oral arguments
30 April 2026
Americas
Penile implant maker’s $17m trade secret award unravels
20 April 2026
Biotechnology
Closing the women's health gap offers ‘benefits for all’
7 April 2026
Europe
European patent offices raise fees
2 April 2026
Americas
Argentina’s patent reset: Why pharma can no longer ignore Latin America's second-largest market
1 April 2026

More features

Fed Circ rejects Nexus’ appeal in generics row with biopharma firm
Hikma triumphs at SCOTUS in landmark skinny-label ruling
Pfizer strikes $10.5 billion oncology deal with Chinese biotech
Chadha & Chadha hires former Remfry & Sagar patent partner
UPC dispute resolution forum opens with ceremony in Slovenia
European court backs AstraZeneca unit in blood cancer combo dispute
Takeda’s China IP head: What pharma is still getting wrong
Boehringer Ingelheim adds ex-Teva executive to patent team